212 related articles for article (PubMed ID: 15347312)
1. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.
Nückel H; Meller D; Steuhl KP; Dührsen U
Eur J Haematol; 2004 Oct; 73(4):258-62. PubMed ID: 15347312
[TBL] [Abstract][Full Text] [Related]
2. [Extranodal marginal zone lymphoma of the ocular adnexa].
Møller A; Specht L; Toft PB; Sjø LD
Ugeskr Laeger; 2008 Nov; 170(45):3660-3. PubMed ID: 18986616
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
Martinelli G; Laszlo D; Ferreri AJ; Pruneri G; Ponzoni M; Conconi A; Crosta C; Pedrinis E; Bertoni F; Calabrese L; Zucca E
J Clin Oncol; 2005 Mar; 23(9):1979-83. PubMed ID: 15668468
[TBL] [Abstract][Full Text] [Related]
4. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
6. A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy.
Celiker H; Toker E; Kaygusuz Atagunduz I
Int Ophthalmol; 2019 Mar; 39(3):687-691. PubMed ID: 29411260
[TBL] [Abstract][Full Text] [Related]
7. Periocular mucosa-associated lymphoid/low grade lymphomas: treatment with antibiotics.
Abramson DH; Rollins I; Coleman M
Am J Ophthalmol; 2005 Oct; 140(4):729-30. PubMed ID: 16226528
[TBL] [Abstract][Full Text] [Related]
8. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
9. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
10. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy.
Wenzel C; Fiebiger W; Dieckmann K; Formanek M; Chott A; Raderer M
Cancer; 2003 May; 97(9):2236-41. PubMed ID: 12712477
[TBL] [Abstract][Full Text] [Related]
11. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
13. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
[TBL] [Abstract][Full Text] [Related]
14. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
[TBL] [Abstract][Full Text] [Related]
15. Conjunctival malt lymphoma successfully treated with single agent rituximab therapy.
Salepci T; Seker M; Kurnaz E; Guler DO; Bilici A; Dane F; Aliustaoglu M; Atesoglu EB; Gumus M; Yaylaci M
Leuk Res; 2009 Mar; 33(3):e10-3. PubMed ID: 18653234
[No Abstract] [Full Text] [Related]
16. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
17. [Non-cytostatic treatment of malignancies. Anti-CD20 monoclonal antibody (Rituximab, Mabthera) in the treatment of non-Hodgkin's lymphoma].
Mayer J; Navrátil M; Vásová J; Vorlícek J
Vnitr Lek; 2001 Sep; 47 Suppl 1():57-62. PubMed ID: 11693064
[TBL] [Abstract][Full Text] [Related]
18. Treatment of primary cutaneous B-cell lymphoma with rituximab.
Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L
J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy for localized low-grade non-Hodgkin's lymphomas.
Tsang RW; Gospodarowicz MK
Hematol Oncol; 2005 Mar; 23(1):10-7. PubMed ID: 16158458
[TBL] [Abstract][Full Text] [Related]
20. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]